Women’s reproductive longevity is perhaps the most important understudied field of medicine. For example, did you know that ovaries age up to 5X faster than any organ in the body?
This “fast ovarian aging” results in infertility, menopause, and an increased number of years spent in poor health. That’s where Gameto, a tech company focused on female reproductive longevity, comes in. They’re on a mission to solve the problem of accelerated ovarian aging and change the trajectory of women's health and equality.
Applying advances in cellular reprogramming, the company has created human reprogrammed cells of the ovary (granulosa cells & oocytes precursors). Gameto has a platform for ovarian therapeutics with sequenced programs improving assisted fertility and the medical burden of menopause.
Join Peter with Gameto CEO Dr. Dina Radenkovic as they discuss the company’s technology, and what this means for the future of women’s reproductive health and human longevity in general.
Dr. Dina Radenkovic Bio: Dr. Radenkovic is CEO of Gameto. She is an MD, originally from Serbia and trained in the UK and the US. She also serves as a Visiting Scientist at the Buck Institute for Research on Aging, as well as a Partner with the global thought leadership forum SALT. Dr. Radenkovic was previously Co-Founder and CSO of longevity clinic Hooke London.
Company Website: HTTPS://GAMETOGEN.COM